Professor Moji Adeyeye has exited National Agency for Food and Drug Administration and Control (NAFDAC), following the expiration of her tenure as the Director General of the agency.
Gatekeepers News reports Adeyeye, who was appointed in 2017, ended her renewable first term in office on November 2.
She has exited the office and an acting head has been appointed for the organisation.
In a leaked internal memo signed by a Deputy Director, Admin and Human Resources Directorate, NAFDAC, Oboli A.U., and dated 17 November, all directors of the agency were notified of the appointment of Monica Eimunjeze as the acting Director-General.
The memo, with reference number NAFDAC/ADM/SM/075, has as its subject: “Appointment of Acting Director General NAFDAC.”
It reads in part, “The management is in receipt of a letter appointing Dr Monica Eimunjeze as the Acting Director General NAFDAC with effect from 12th November 2022.
“I am therefore directed to bring this development to you for information and guidance.”
According to an internal source, before Eimunjeze was appointed the Ag. Director, Adeyeye while heading on an official assignment on November 4, 2022, requested Eimunjeze who was the then Director Drug Registration and Regulatory Affairs to act on her behalf except on financial grounds.
It is, however, unclear if Adeyeye tendered her exit letter during the official trip which she was supposed to return on December 9, 2022.
About NAFDAC’s New Boss – Monica Eimunjeze
According to NAFDAC, the New Acting Director General’s profile indicates that she studied Pharmacy at Ahmadu Bello University (ABU) Zaria, and graduated in 1986.
Eimunjeze later bagged her Doctor of Pharmacy (Pharm D) from Mercer University, Atlanta Georgia, and a Master of Science (MSc) in Biotechnology, Innovation, and Regulatory Science from Purdue University.
She is said to have a varied experience in the pharmaceutical sector spanning different areas of practice, having had her industrial exposure with GlaxoSmithKline from 1989 to 1996.
Eimunjeze served the company in various capacities and held different positions including as a medical representative, quality control manager, and as regulatory affairs manager.
Until her appointment as the Acting Director General, Eimunjeze was NAFDAC’s Director of Registration and Regulatory Affairs.
She was said to have previously served as the Technical Assistant to the Director General of NAFDAC and as the Director, Drug Evaluation and Research.
